» Articles » PMID: 29744564

Effects of Chlorhexidine Gluconate Oral Care on Hospital Mortality: a Hospital-wide, Observational Cohort Study

Overview
Specialty Critical Care
Date 2018 May 11
PMID 29744564
Citations 37
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Chlorhexidine oral care is widely used in critically and non-critically ill hospitalized patients to maintain oral health. We investigated the effect of chlorhexidine oral care on mortality in a general hospitalized population.

Methods: In this single-center, retrospective, hospital-wide, observational cohort study we included adult hospitalized patients (2012-2014). Mortality associated with chlorhexidine oral care was assessed by logistic regression analysis. A threshold cumulative dose of 300 mg served as a dichotomic proxy for chlorhexidine exposure. We adjusted for demographics, diagnostic category, and risk of mortality expressed in four categories (minor, moderate, major, and extreme).

Results: The study cohort included 82,274 patients of which 11,133 (14%) received chlorhexidine oral care. Low-level exposure to chlorhexidine oral care (≤ 300 mg) was associated with increased risk of death [odds ratio (OR) 2.61; 95% confidence interval (CI) 2.32-2.92]. This association was stronger among patients with a lower risk of death: OR 5.50 (95% CI 4.51-6.71) with minor/moderate risk, OR 2.33 (95% CI 1.96-2.78) with a major risk, and a not significant OR 1.13 (95% CI 0.90-1.41) with an extreme risk of mortality. Similar observations were made for high-level exposure (> 300 mg). No harmful effect was observed in ventilated and non-ventilated ICU patients. Increased risk of death was observed in patients who did not receive mechanical ventilation and were not admitted to ICUs. The adjusted number of patients needed to be exposed to result in one additional fatality case was 47.1 (95% CI 45.2-49.1).

Conclusions: These data argue against the indiscriminate widespread use of chlorhexidine oral care in hospitalized patients, in the absence of proven benefit in specific populations.

Citing Articles

Development of Solid Nanosystem for Delivery of Chlorhexidine with Increased Antimicrobial Activity and Decreased Cytotoxicity: Characterization and In Vitro and In Ovo Toxicological Screening.

Danila A, Rominu M, Munteanu K, Moaca E, Geamantan-Sirbu A, Olariu I Molecules. 2025; 30(1.

PMID: 39795218 PMC: 11721946. DOI: 10.3390/molecules30010162.


The comparative effect of propolis and chlorhexidine mouthwash on oral nitrite-producing bacteria and blood pressure regulation.

Bescos R, Toit L, Redondo-Rio A, Warburton P, Nicholas T, Kiernan M J Oral Microbiol. 2024; 17(1):2439636.

PMID: 39691165 PMC: 11650436. DOI: 10.1080/20002297.2024.2439636.


Strategies for the prevention of periodontal disease and its impact on general health: Latin America and the Caribbean Consensus 2024.

Duque Duque A, Chaparro Padilla A, Almeida M, Marin Jaramillo R, Romanelli H, Lafaurie Villamil G Braz Oral Res. 2024; 38(suppl 1):e120.

PMID: 39607151 PMC: 11665974. DOI: 10.1590/1807-3107bor-2024.vol38.0120.


Removal of Chlorhexidine for Ventilator-Associated Pneumonia Prevention with a Dentist Composing the Intensive Care Unit Team.

Pains M, Vieira I, Figueiredo A, Diniz S, Figueiredo P J Multidiscip Healthc. 2024; 17:5299-5308.

PMID: 39575228 PMC: 11579132. DOI: 10.2147/JMDH.S476253.


The chemical biology of dinitrogen trioxide.

Moller M, Vitturi D Redox Biochem Chem. 2024; 8.

PMID: 38957295 PMC: 11218869. DOI: 10.1016/j.rbc.2024.100026.


References
1.
Muscedere J, Martin C, Heyland D . The impact of ventilator-associated pneumonia on the Canadian health care system. J Crit Care. 2008; 23(1):5-10. DOI: 10.1016/j.jcrc.2007.11.012. View

2.
Torres A, Niederman M, Chastre J, Ewig S, Fernandez-Vandellos P, Hanberger H . International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: Guidelines for the management of hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the.... Eur Respir J. 2017; 50(3). DOI: 10.1183/13993003.00582-2017. View

3.
Blot S, Poelaert J, Kollef M . How to avoid microaspiration? A key element for the prevention of ventilator-associated pneumonia in intubated ICU patients. BMC Infect Dis. 2014; 14:119. PMC: 4289393. DOI: 10.1186/1471-2334-14-119. View

4.
Melsen W, Rovers M, Bonten M . Ventilator-associated pneumonia and mortality: a systematic review of observational studies. Crit Care Med. 2009; 37(10):2709-18. DOI: 10.1097/ccm.0b013e3181ab8655. View

5.
Plantinga N, Wittekamp B, Leleu K, Depuydt P, Van den Abeele A, Brun-Buisson C . Oral mucosal adverse events with chlorhexidine 2% mouthwash in ICU. Intensive Care Med. 2016; 42(4):620-621. PMC: 5413521. DOI: 10.1007/s00134-016-4217-7. View